NASDAQ Biotechnology Index


Also found in: Wikipedia.

NASDAQ Biotechnology Index

An index tracking pharmaceutical, biological research and similar companies whose shares trade on NASDAQ. It is weighted under a modified market capitalization scheme; the securities that compose it are updated semi-annually.
References in periodicals archive ?
The Nasdaq biotechnology index was up about 2 percent.
In 2014, the Life Sciences sector was the segment to receive the least investment on the TSX/TSXV while the NASDAQ Biotechnology Index outpaced the NASDAQ Composite Index by nearly 3:1 over the past three years.
A 456 per cent surge in the Nasdaq Biotechnology Index has driven its price-sales ratio to an 11-year high of 9.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.
The Nasdaq biotechnology index fell seven per cent for the week.
Company's benchmark, the NASDAQ Biotechnology Index measured in
Biotechnology companies in particular had a standout 2013, with the Nasdaq Biotechnology Index gaining 66 per cent, topping a 30 per cent increase for the Standard & Poor's 500, and closing on Thursday at a record high of 2,449.
The ETFs seek to provide 200 per cent or -200 per cent of the return of the NASDAQ Biotechnology Index for a single day.
Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is pleased to announce that it has been selected to join the NASDAQ Biotechnology Index effective with the market open on May 19, 2008.
AVANIR Pharmaceuticals has been selected for addition to the NASDAQ Biotechnology Index effective Monday, November 20.
has been selected for inclusion in the Nasdaq Biotechnology Index, which tracks the performance of the pharmaceutical and biotechnology market sectors.
A thorough analysis of companies listed on the NASDAQ Biotechnology Index (NBI) revealed that while less than 10 percent of these companies' currently marketed products are biologic drugs -- pharmaceuticals derived from living organisms -- these products comprise a hefty 40 percent of the companies' drug pipelines.